Trial Information

A Phase I Trial of Weekly Paclitaxel in Combination With Bavituximab in Patients With Her-2 Negative Metastatic Breast Cancer

PRIMARY OBJECTIVES:

I. To determine the safety, feasibility, and tolerability of combining paclitaxel with
weekly bavituximab therapy.

SECONDARY OBJECTIVES:

I. To describe changes in pharmacodynamic markers and coagulation markers in response to
single agent and combined therapy.

OUTLINE:

Patients receive paclitaxel intravenously (IV) on days 1, 8, and 15 and bavituximab IV on
days 1, 8, 15, and 22 (days 15 and 22 only of course 1). Courses repeat every 4 weeks in the
absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically.

- Prothrombin time international normalized ratio within institutional normal limits

- Activated partial thromboplastin time =< 1.5 x ULN

- New York Heart Association classification I or II

- Female patients must have a negative urine pregnancy test at prestudy (not applicable
to patients with bilateral oophorectomy and/or hysterectomy or to those patients who
are postmenopausal)

Exclusion Criteria:

- Known history of bleeding diathesis or coagulopathy (e.g., von Willebrand Disease,
Hemophilia)

- Any current evidence of clinically significant active bleeding

- Any history of significant thromboembolic events (i.e., deep vein thrombosis or
pulmonary thromboembolism) within the last five years or requirement for ongoing
therapy with oral or parenteral anticoagulants; central venous catheter-related
thrombosis > 12 months ago and low dose anticoagulants to maintain patency of lines
are allowed; patients taking anticoagulants (e.g., prophylactic heparin or
enoxaparin) are required to observe the washout period of 1 week prior to study drug
infusion on Study Day 1

- More than one prior chemotherapy regimen for metastatic disease (prior adjuvant
chemotherapy or any number of prior hormonal therapies are allowed)

- Chemotherapy, immunotherapy or radiotherapy within 2 weeks of Study Day 1 or not
having recovered from significant treatment-related side effects due to agents
administered previously; patients who have receive nitrosoureas and mitomycin C
therapy are required to observe the washout period of 6 weeks prior to study drug
infusion on Study Day 1

- Any history of angina pectoris, coronary artery disease or cerebrovascular accident,
or transient ischemic attack

- A history of any condition requiring anti-platelet therapy (e.g., phosphodiesterase
inhibitors, adenosine diphosphate receptor antagonists) with the exception of general
cardiovascular prophylaxis with aspirin

Type of Study:

Study Design:

Outcome Measure:

Determination of grade 3 or higher toxicities associated with the combination therapy as classified using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

Outcome Time Frame:

One year

Safety Issue:

Yes

Principal Investigator

Alison Stopeck

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Arizona

Authority:

United States: Food and Drug Administration

Study ID:

10-0884-04

NCT ID:

NCT01288261

Start Date:

January 2011

Completion Date:

Related Keywords:

HER2-negative Breast Cancer

Male Breast Cancer

Recurrent Breast Cancer

Stage IIIC Breast Cancer

Stage IV Breast Cancer

Breast Neoplasms

Breast Neoplasms, Male

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.